Pacira Pharmaceuticals Inc (PCRX)

Financial leverage ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total assets	US$ in thousands	1,574,390	1,534,460	1,542,380	1,523,420	1,681,200	1,734,360	1,733,990	1,891,480	2,075,350	1,356,000	1,325,830	1,287,550	1,274,510	1,220,270	866,111	821,379	831,065	807,489	787,843	719,156
Total stockholders’ equity	US$ in thousands	870,130	831,551	807,975	768,041	775,010	770,123	756,636	709,576	730,408	718,602	687,168	650,818	619,688	584,690	388,148	374,036	354,944	346,162	341,650	327,519
Financial leverage ratio		1.81	1.85	1.91	1.98	2.17	2.25	2.29	2.67	2.84	1.89	1.93	1.98	2.06	2.09	2.23	2.20	2.34	2.33	2.31	2.20

December 31, 2023 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,574,390K ÷ $870,130K
= 1.81

The financial leverage ratio of Pacira BioSciences Inc has been fluctuating in recent quarters, indicating changes in the company's level of debt and equity financing. The ratio has decreased from 2.67 in Q1 2022 to 1.81 in Q4 2023, suggesting a reduction in the proportion of debt relative to equity in the company's capital structure.

While a decreasing financial leverage ratio can indicate a lower reliance on debt financing, it may also signal a conservative approach to managing the company's capital structure and financial risk. However, it is essential to assess the overall financial health of the company and its ability to meet its financial obligations, as a low financial leverage ratio may limit potential growth opportunities.

It is recommended to further analyze Pacira BioSciences Inc's financial leverage ratio in conjunction with other financial ratios and metrics to gain a more comprehensive understanding of the company's financial position and performance.